UniProtKB/Swiss-Prot Q13496 : Variant p.Pro205Leu
Myotubularin
Gene: MTM1
Feedback ?
Variant information
Variant position:
205
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Proline (P) to Leucine (L) at position 205 (P205L, p.Pro205Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In CNMX; severe; dramatic decrease in phosphatase activity; abolishes interaction with DES and MTMR12.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
205
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
603
The length of the canonical sequence.
Location on the sequence:
ITFINKCYELCDTYPALLVV
P YRASDDDLRRVATFRSRNRI
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human ITFINKCYELCDTYPALLVVP YRASDDDLRRVATFRSRNRI
Mouse ISFINKCYELCETYPALLVVP YRTSDDDLRRIATFRSRNRL
Rat ISFVNQRYELCDTYPALLVVP YRASDDDLRRVATFRSRNRI
Bovine ITFINKCYKLCDTYPALLVVP YRASDEDLRRVATFRSRNRI
Xenopus laevis ITFINRNYELCDTYPPLLVVP YSASEEDLKRVAAFRSRNRI
Xenopus tropicalis ITFINKNYELCDTYPPLLVVP YSASEEDLKKVAAFRSRNRI
Baker's yeast ---------IASTYPTLNPLF CGA-------IARVFAATSI
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 603
Myotubularin
Domain
163 – 538
Myotubularin phosphatase
Mutagenesis
206 – 206
Y -> A. Disrupts interaction with DES. Does not affect lipid phosphatase activity.
Mutagenesis
209 – 209
S -> A. Disrupts interaction with DES. Does not affect lipid phosphatase activity.
Mutagenesis
220 – 220
R -> A. Loss of activity.
Literature citations
Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate.
Taylor G.S.; Maehama T.; Dixon J.E.;
Proc. Natl. Acad. Sci. U.S.A. 97:8910-8915(2000)
Cited for: FUNCTION; CATALYTIC ACTIVITY; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS LEU-205; LEU-241; ASN-376; ARG-378 AND CYS-397; MUTAGENESIS OF CYS-375;
Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle.
Hnia K.; Tronchere H.; Tomczak K.K.; Amoasii L.; Schultz P.; Beggs A.H.; Payrastre B.; Mandel J.L.; Laporte J.;
J. Clin. Invest. 121:70-85(2011)
Cited for: FUNCTION; INTERACTION WITH DES; CHARACTERIZATION OF VARIANTS GLY-184; LEU-205; CYS-241 AND GLN-421; MUTAGENESIS OF HIS-181; TYR-206; SER-209; LYS-255; LYS-269; ASP-278; CYS-375; ASP-380 AND SER-420;
Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish.
Gupta V.A.; Hnia K.; Smith L.L.; Gundry S.R.; McIntire J.E.; Shimazu J.; Bass J.R.; Talbot E.A.; Amoasii L.; Goldman N.E.; Laporte J.; Beggs A.H.;
PLoS Genet. 9:E1003583-E1003583(2013)
Cited for: FUNCTION; INTERACTION WITH MTMR12; MUTAGENESIS OF CYS-375 AND 421-ARG--PHE-603; VARIANTS CNMX PHE-49; CYS-69; GLY-184; LEU-205; CYS-241 AND GLN-421;
Mutations in the MTM1 gene implicated in X-linked myotubular myopathy.
Laporte J.; Guiraud-Chaumeil C.; Vincent M.-C.; Mandel J.-L.; Tanner S.M.; Liechti-Gallati S.; Wallgren-Pettersson C.; Dahl N.; Kress W.; Bolhuis P.A.; Fardeau M.; Samson F.; Bertini E.;
Hum. Mol. Genet. 6:1505-1511(1997)
Cited for: VARIANTS CNMX CYS-69; PHE-70; PRO-87; SER-189; LEU-205; PRO-229; CYS-241; ASN-376; ARG-378; CYS-397; ALA-402; GLN-421; ASN-431; ASN-433 AND PRO-469;
Characterization of 34 novel and six known MTM1 gene mutations in 47 unrelated X-linked myotubular myopathy patients.
Tanner S.M.; Schneider V.; Thomas N.S.T.; Clarke A.; Lazarou L.; Liechti-Gallati S.;
Neuromuscul. Disord. 9:41-49(1999)
Cited for: VARIANTS CNMX LEU-205; THR-225; CYS-230; ARG-232; CYS-241; ARG-402 AND TYR-444;
Characterization of mutations in fifty North American patients with X-linked myotubular myopathy.
Herman G.E.; Kopacz K.; Zhao W.; Mills P.L.; Metzenberg A.; Das S.;
Hum. Mutat. 19:114-121(2002)
Cited for: VARIANTS CNMX PHE-49; CYS-69; SER-179; ILE-186; LEU-205; MET-227; PRO-228; CYS-241; GLY-279; ARG-378; PRO-391; CYS-397; ARG-402 AND GLN-421;
Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype.
Biancalana V.; Caron O.; Gallati S.; Baas F.; Kress W.; Novelli G.; D'Apice M.R.; Lagier-Tourenne C.; Buj-Bello A.; Romero N.B.; Mandel J.-L.;
Hum. Genet. 112:135-142(2003)
Cited for: VARIANTS CNMX LYS-47 DEL; ASP-68; PRO-69; SER-69; PHE-70; LYS-180; LEU-184; SER-202; LEU-205; THR-226; CYS-230; CYS-241; CYS-346; GLY-364; ASP-389; CYS-397; GLN-421; PRO-469; PRO-470 AND TYR-481;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.